Characterization of Myocardial Injury in Patients With COVID-19

Gennaro Giustino, MD; Lori B. Croft, MD; Giulio G. Stefanini, MD, PHD; Renato Bragato, MD; Jeffrey J. Silbiger, MD; Marco Vicenzi, MD; Tatyana Danilov, MD; Nina Kukar, MD; Nada Shaban, MD; Annapoorna Kini, MD; Anton Camaj, MD, MS; Solomon W. Bienstock, MD; Eman R. Rashed, MD; Karishma Rahman, MD, PHD; Connor P. Oates, MD; Samantha Buckley, BS; Lindsay S. Elbaum, MD; Derya Arkonac, MD; Ryan Fiter, MD; Ranbir Singh, MD; Emily Li, MD; Victor Razuk, MD; Sam E. Robinson, MD; Michael Miller, MS; Benjamin Bier, MD; Valeria Donghi, MD; Marco Pisaniello, MD; Riccardo Mantovani, MD; Giuseppe Pinto, MD; Irene Rota, MD; Sara Baggio, MD; Mauro Chiarito, MD; Fabio Fazzari, MD; Ignazio Cusmano, MD; Mirko Curzi, MD; Richard Ro, MD; Waqas Malick, MD; Mazullah Kamran, MD; Roopa Kohli-Seth, MD; Adel M. Bassily-Marcus, MD; Eric Neibart, MD; Gregory Serrao, MD; Gila Perk, MD; Donna Mancini, MD; Vivek Y. Reddy, MD; Sean P. Pinney, MD; George Dangas, MD, PHD; Francesco Blasi, MD, PHD; Samin K. Sharma, MD; Roxana Mehran, MD; Gianluigi Condorelli, MD; Gregg W. Stone, MD; Valentin Fuster, MD, PHD; Stamatios Lerakis, MD, PHD; Martin E. Goldman, MD


J Am Coll Cardiol. 2020;76(18):2043-2055. 

In This Article


Patients with COVID-19 and myocardial injury have a broad spectrum of cardiac abnormalities, although approximately one-third of such patients show no evidence of structural cardiac disease. Myocardial injury is associated with increased risk of in-hospital mortality particularly in the presence of cardiac structural abnormalities detected by TTE. TTE evaluation should be considered in patients with COVID-19 and biomarker evidence of myocardial injury to characterize the underlying cardiac substrate, for risk stratification, and to potentially guide management strategies.